Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

Bristol Myers Squibb (BMY) has recently outperformed its peers, with shares up +6.7% over the past month, and reported a significant beat on Q4 revenue and EPS, marking its fourth consecutive quarter of exceeding consensus estimates for both. However, forward-looking consensus estimates project a decline in current quarter EPS by -8.3% year-over-year to $1.65, alongside anticipated revenue contractions for the current and next fiscal years. Despite a favorable 'A' valuation grade indicating undervaluation relative to peers, BMY holds a Zacks Rank #3 (Hold), suggesting near-term performance in line with the broader market.

Analysis

Bristol Myers Squibb (BMY) has demonstrated significant recent share price momentum, with a +6.7% return over the past month that outpaces both the S&P 500 composite's +1.6% and its industry's +2.5% gain. This performance is supported by a strong history of exceeding expectations, as seen in the last reported quarter where revenues of $12.27 billion and EPS of $1.46 represented surprises of +7.66% and +36.45% respectively, marking the fourth consecutive quarter of beating consensus on both metrics. However, this backward-looking strength is contrasted by a weakening forward outlook. Consensus estimates project a current quarter EPS decline of -8.3% and revenue contractions of -2.4% for the current fiscal year and -8.2% for the next. While the consensus EPS estimate for the current fiscal year has been revised up by +3.7% over the last 30 days, estimates for the current quarter have been revised down -1.4%. Despite these headwinds, the stock's valuation appears attractive, earning a Zacks Value Style Score of 'A'. The resulting Zacks Rank #3 (Hold) indicates that the negative forward guidance is largely offsetting the positive valuation and recent performance, suggesting the stock may perform in line with the market in the near term.

Key Decisions for Investors

• Investors should weigh the company's attractive 'A' grade for valuation and consistent history of earnings beats against the cautionary forward guidance, which projects revenue declines of -2.4% and -8.2% in the current and next fiscal years.
• Given the projected -8.3% year-over-year EPS decline for the current quarter, upcoming earnings announcements will be critical to validate whether the company can defy the negative consensus and continue its trend of positive surprises.
• The Zacks Rank #3 (Hold) suggests that while value-oriented investors might find the current discounted price appealing, the expectation of market-parallel performance and declining fundamentals warrants caution for those seeking near-term alpha.